Cardiology Pharmaceuticals

SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes

tirzepatide injection

The largest and longest tirzepatide study to date just confirmed that Eli Lilly’s Mounjaro has surpassed its older GLP-1, Trulicity, in practically every way, with significant gains when it comes to cardiovascular benefits.

  • Dual GIP/GLP-1 receptor agonists like tirzepatide target two incretin pathways simultaneously, potentially offering advantages over single GLP-1 agonists.
  • The REWIND trial studies already established Trulicity’s definitive CV benefits.
  • This represents the first head-to-head comparison between incretin therapies in a cardiovascular outcomes trial.

The SURPASS-CVOT study represents the most comprehensive incretin analysis to date, comparing MACE rates in 13k T2D patients with ASCVD on either Mounjaro or Trulicity over a four year follow-up, finding that…

  • MACE risk was 8% lower with Mounjaro.
  • Mounjaro achieved non-inferiority per the study’s statistical cutoff.

Beyond meeting the study’s primary MACE endpoint, Mounjaro also demonstrated significant advantages across several secondary outcomes at 36 months, including…

  • All-cause mortality reduced by 16%.
  • Slowed kidney function decline by 3.54 mL/min/1.73 m² in high risk CKD patients.
  • Superior A1C reduction (1.73% vs 0.90%).
  • Greater weight loss (12.06% vs 4.95%).

Pre-specified indirect analyses of the study also suggest Mounjaro’s benefits may extend beyond existing GLP-1 therapies when compared to placebo controls.

  • Indirect comparison to REWIND placebo data showed 28% MACE reduction.
  • All-cause mortality reduction versus placebo reached 39%.

The Takeaway

SURPASS-CVOT could be a watershed moment for diabetes management, providing the first head-to-head evidence that dual incretin receptor activation helps protect the heart while delivering clinically meaningful advantages in mortality and kidney preservation. If nothing else, it asserts Mounjarno is a significant improvement over Lilly’s older Trulicity.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology August 28, 2025

Cardiologists, Practice What You Preach! August 28, 2025

Cardiologists might be struggling with the same lifestyle challenges they counsel patients about, as a national survey of ACC members revealed significant gaps between what physicians’ recommend and how they act. The ACC CardioSurve study surveyed 166 U.S. cardiologists about their training in lifestyle medicine and clinical recommendations across all six lifestyle pillars, revealing some […]

Obesity Care August 25, 2025

GLP-1s Work, But Not for Free August 25, 2025

Real-world semaglutide (Wegovy) patients might be experiencing a healthcare cost paradox, after a recent analysis in JAMA showed that GLP-1s successfully reduce weight and improve cardiovascular risk factors, but lead to increased patient healthcare expenditures in the short term. The real-world analysis examined 23.5k adults prescribed semaglutide between January 2018 and January 2025 across two […]

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!